REFERENCES
1. Jakobsen E, Olsen KE, Bliddal M, Hornbak M, Persson GF, Green A. Forecasting lung cancer incidence, mortality, and prevalence to year 2030. BMC Cancer. 2021;21:985.
2. Araki T, Kanda S, Horinouchi H, Ohe Y. Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. Jpn J Clin Oncol. 2023;53:547-61.
3. Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113-25.
4. Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046-61.
5. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-34.
6. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239-46.
7. Zhou C, Wu Y, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735-42.
8. Goss G, Tsai C, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17:1643-52.
9. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-8.
10. Wu Y, Zhou C, Hu C, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213-22.
11. Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130-40.
12. Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers. 2023;15:841.
13. Tao W, Tang X, Jiao X, et al. Effectiveness of interventions for increasing lung cancer screening uptake: a systematic review and meta-analysis of randomized clinical trials. Prev Med. 2026;203:108489.
14. Tang X, Pang Y, Zhu P, et al. Cell apoptosis and glucocorticoid-induced osteonecrosis. Med Res. 2025;1:207-25.
15. Fu K, Xie F, Wang F, Fu L. Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 2022;15:173.
16. Piper-Vallillo AJ, Sequist LV, Piotrowska Z. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review. J Clin Oncol. 2020;38:2926-36.
17. Lee J, Piotrowska Z, Soo R, Cho BC, Lim SM. Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer. Ther Adv Med Oncol. 2022;14:17588359221144099.
18. Blaquier JB, Ortiz-Cuaran S, Ricciuti B, Mezquita L, Cardona AF, Recondo G. Tackling osimertinib resistance in EGFR-mutant non-small cell lung cancer. Clin Cancer Res. 2023;29:3579-91.
19. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725-37.
20. Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M. Mechanisms of resistance to osimertinib. J Thorac Dis. 2020;12:2851-8.
21. Bertoli E, De Carlo E, Del Conte A, et al. Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it? Int J Mol Sci. 2022;23:6936.
22. Zeng Y, Yu D, Tian W, Wu F. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. Curr Opin Oncol. 2022;34:54-65.
23. Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24:6195-203.
24. Liao Y, Tsai C, Huang H. Optimizing osimertinib for NSCLC: targeting resistance and exploring combination therapeutics. Cancers. 2025;17:459.
25. Cerbone L, Benitez JC, Planchard D, Genova C. An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update. Expert Opin Pharmacother. 2021;22:809-19.
26. Veccia A, Dipasquale M, Lorenzi M, et al. Osimertinib in the treatment of epidermal growth factor receptor-mutant early and locally advanced stages of non-small-cell lung cancer: current evidence and future perspectives. Cancers. 2025;17:668.
27. Carlisle JW, Ramalingam SS. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncol. 2019;15:805-16.
28. Nie N, Li J, Zhang J, et al. First-line osimertinib in patients with EGFR-mutated non-small cell lung cancer: effectiveness, resistance mechanisms, and prognosis of different subsequent treatments. Clin Med Insights Oncol. 2022;16:11795549221134735.
29. Pan K, Ramalingam SS. Rapidly evolving therapeutic advances for classical EGFR-mutant NSCLC. Front Oncol. 2025;15:1732467.
30. Li L, Huang Q, Sun J, et al. Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies. Acta Oncol. 2022;61:1347-53.
31. Yi L, Fan J, Qian R, Luo P, Zhang J. Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: a meta‐analysis. Int J Cancer. 2019;145:284-94.
32. Liu J, Li X, Shao Y, Guo X, He J. The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis. Medicine. 2020;99:e21826.
33. Chen P, Chen F, Lei J, Zhou B. Curative effectiveness and safety of osimertinib in the treatment for non-small cell lung cancer: a meta-analysis of the experimental evidence. Onco Targets Ther. 2018;11:9033-47.
34. Huang L, Huang H, Zhou X, et al. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: a meta-analysis. Medicine. 2019;98:e17705.
35. Wang N, Zhang Y, Mi Y, et al. Osimertinib for EGFR-mutant lung cancer with central nervous system metastases: a meta-analysis and systematic review. Ann Palliat Med. 2020;9:3038-47.
36. Zhang H, Chen J, Liu T, Dang J, Li G. First-line treatments in EGFR-mutated advanced non-small cell lung cancer: a network meta-analysis. PLoS ONE. 2019;14:e0223530.
37. Holleman MS, Van Tinteren H, Groen HJM, Al MJ, Uyl-de Groot CA. First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. Onco Targets Ther 2019;12:1413-21.
38. Qureshi Z, Altaf F, Jamil A, Siddique R. Meta-analysis of targeted therapies in EGFR-mutated non-small cell lung cancer: efficacy and safety of osimertinib, erlotinib, and gefitinib as first-line treatment. Am J Clin Oncol. 2025;48:44-54.
39. Zhao M, Zhang J, Gao J, Wang J, Ma Z. Osimertinib efficacy and safety in treating epidermal growth factor receptor mutation-positive advanced non-small‐cell lung cancer: a meta-analysis. Clin Pharm Drug Dev. 2024;14:5-10.
40. Priantti JN, Fujiwara Y, Aquino De Moraes FC, et al. Safety and efficacy of osimertinib in patients with non-small-cell lung cancer and uncommon tumoral epidermal growth factor receptor mutations: a systematic review and single-arm meta-analysis. JCO Precis Oncol. 2024;8:e2400331.
41. Cui S, Zhang Y, Liu L, et al. The efficacy and safety of Osimertinib in advanced non-small cell lung cancer patients with Thr790Met resistance mutations: a systematic review and meta-analysis. Ann Palliat Med. 2021;10:1851-60.
42. Tan DS, Nadal E, Cheema P, et al. TROPION-lung15: a randomized phase III study of osimertinib combined with datopotamab deruxtecan (Dato-DXd) or Dato-DXd alone versus platinum-doublet chemotherapy in patients withEGFR-mutated advanced non-small cell lung cancer and whose disease has progressed on prior osimertinib. Ther Adv Med Oncol. 2025;17:17588359251385410.
43. Ríos-Hoyo A, Moliner L, Arriola E. Acquired mechanisms of resistance to osimertinib -the next challenge. Cancers. 2022;14:1931.
44. Tsubata Y, Tanino R, Isobe T. Current therapeutic strategies and prospects for EGFR mutation-positive lung cancer based on the mechanisms underlying drug resistance. Cells. 2021;10:3192.
45. He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review). Int J Oncol. 2021;59:90.
46. Melosky B, Banerji S, Blais N, et al. Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer. Curr Oncol. 2020;27:146-55.
47. Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-23.
48. Herbst RS, Wu Y, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41:1830-40.
49. Herbst RS, Tsuboi M, John T, et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 2023;41:LBA3.
50. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389:137-47.
51. Xie J, Chen C, Zhang B, et al. Abstract CT164: efficacy and safety of osimertinib therapy in high-risk stage I EGFRm NSCLC after R0 resection (OSTAR): a phase II, prospective, single-arm study. Cancer Res. 2025;85:CT164.
52. Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study. J Clin Oncol. 2024;42:3105-14.
53. Aredo JV, Urisman A, Gubens MA, et al. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer. J Clin Oncol. 2023;41:8508.
54. Lyu C, Fang W, Ma H, et al. Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS). J Clin Oncol. 2021;39:8524.
55. Lu S, Kato T, Dong X, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC. N Engl J Med. 2024;391:585-97.
56. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41-50.
57. Planchard D, Boyer MJ, Lee J, et al. Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25:2058-63.
58. Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290-7.
59. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935-48.
60. Jänne PA, Planchard D, Kobayashi K, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2026;394:27-38.
61. Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL Study. Eur J Cancer. 2023;185:83-93.
62. Fukui T, Mamesaya N, Takahashi T, et al. A prospective phase II trial of first-line osimertinib for patients with EGFR mutation-positive NSCLC and poor performance status (OPEN/TORG2040). J Thorac Oncol. 2025;20:665-75.
63. Mamesaya N, Fukui T, Takahashi T, et al. A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040). J Clin Oncol. 2024;42:8552.
64. Park C, Cho H, Choi Y, Oh I, Kim Y. A phase II trial of osimertinib as the first-line treatment of non-small cell lung cancer harboring activating EGFR mutations in circulating tumor DNA: liquidlung-O-cohort 1. Cancer Res Treat. 2021;53:93-103.
65. Mok TS, Wu Y, Ahn M, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629-40.
66. Akamatsu H, Katakami N, Okamoto I, et al. Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial. Cancer Sci. 2018;109:1930-8.
67. Yang JC, Ahn M, Kim D, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35:1288-96.
68. Park C, Cho H, Choi Y, Oh I, Kim Y. A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-cohort 2. Cancer Res Treat. 2019;51:777-87.
69. Ahn M, Han J, Kim D, et al. Osimertinib in patients with T790M-positive advanced non-small cell lung cancer: Korean subgroup analysis from phase II studies. Cancer Res Treat. 2020;52:284-91.
70. Cho JH, Lim SH, An HJ, et al. Osimertinib for Patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38:488-95.
71. Okuma Y, Kubota K, Shimokawa M, et al. First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial. JAMA Oncol. 2024;10:43.
72. Okuma Y, Kubota K, Shimokawa M, et al. Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): a phase 2 study. J Clin Oncol. 2023;41:9045.
73. Eide IJZ, Stensgaard S, Helland Å, et al. Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Transl Lung Cancer Res. 2022;11:953-63.
74. Kim TM, Ock CY, Kim M, et al. 1529P - phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean cancer study group (LU17-19). Ann Oncol. 2019;30:v628.
75. Bhatt VR, D’souza SP, Smith LM, et al. Epidermal growth factor receptor mutational status and brain metastases in non-small-cell lung cancer. J Glob Oncol. 2017;3:208-17.
76. Wu Y, Ahn M, Garassino MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol. 2018;36:2702-9.
77. Xing L, Pan Y, Shi Y, et al. Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases: the APOLLO study. Clin Cancer Res. 2020;26:6168-75.
78. Marinis FD, Wu Y, De Castro G, et al. ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. Future Oncol. 2019;15:3003-14.
79. Lee JH, Kim EY, Park C, et al. Real-world study of osimertinib in Korean patients with epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. Cancer Res Treat. 2023;55:112-22.
80. Zhang D, Liu X, Shen F, et al. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. Transl Lung Cancer Res. 2023;12:2229-44.
81. Chang G, Shih J, Yu C, et al. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer. PLoS ONE. 2024;19:e0303046.
82. Chen H, Chen C, Liao W, et al. Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs. BMC Pulm Med. 2024;24:517.
83. Tiwari A, Singh AK, Noronha V, et al. Real-world experience of first-line osimertinib in EGFR mutated non-small cell lung cancers from a tertiary cancer center, India. South Asian J Cancer. 2024;14:785-90.
84. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240-7.
85. Takahama T, Azuma K, Shimokawa M, et al. Plasma screening for the T790M mutation ofEGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: west Japan Oncology Group 8815L/LPS study. Cancer. 2020;126:1940-8.
86. Tsuboi M, Weder W, Escriu C, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021;17:4045-55.
87. Nicoś M, Sroka-bartnicka A, Kalinka E, Krawczyk P. Possibilities of overcoming resistance to osimertinib in NSCLC patients with mutations in the EGFR gene. Cancers. 2025;17:563.
88. Yamaguchi T, Masago K, Sasaki E, Kuroda H, Matsushita H, Horio Y. EML4-ALK variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC. Cancer Genet. 2024;280-1:13-6.
89. Ntzifa A, Marras T, Georgoulias V, Lianidou E. Liquid biopsy for the management of NSCLC patients under osimertinib treatment. Crit Rev Clin Lab Sci. 2024;61:347-69.
90. Zhang W, Xiong J, Li Y, et al. Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysis. Ther Adv Med Oncol. 2025;17:17588359251338046.
91. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35:77-90.
92. Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41:5363-75.
93. Sands J, Ahn M, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025;43:1254-65.
94. Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON. Cancer Discov. 2023;13:98-113.
95. Yang JCH, Ellers-Lenz B, Straub J, Johne A, Wu YL. 536TiP - INSIGHT 2: tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: a phase II trial in progress study. Ann Oncol. 2019;30:ix181.
96. Pan J, Cai X, Cao Z, Pan J, Zheng H. Osimertinib in the treatment of EGFR mutation-positive advanced non-small cell lung cancer: a meta-analysis. Pharmacology. 2023;108:8-16.
97. Lin J, Zhang C, Weng J, Wang S. Efficacy and safety of Osimertinib and other third-generation EGFR TKIs in advanced NSCLC: a systematic review and meta-analysis. Discov Oncol. 2026;17:232.
98. Zhao Y, Liu J, Cai X, et al. Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis. BMJ. 2019;367:l5460.
99. Alanazi A, Yunusa I, Elenizi K, Alzarea AI. Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis. Lung Cancer Manag. 2020;10:LMT43.
100. Xie T, Zou Z, Liu C, et al. Front-line therapy in EGFR exon 19 deletion and 21 Leu858Arg mutations in advanced non-small cell lung cancer: a network meta-analysis. Evid Based Complement Alternat Med. 2021;2021:1-15.
101. Chan S, Choi HC, Lee VH. Overall survival benefits of first-line treatments for Asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis. JTO Clin Res Rep. 2022;3:100322.
102. Du W, Li A, Xiao B, et al. First‐line third‐generation EGFR tyrosine kinase inhibitor monotherapy for advanced EGFR‐mutated non‐small cell lung cancer: a systematic review and network meta‐analysis. MedComm. 2025;6:e70393.
103. Zhang W, Zhang X, Zhao W, et al. What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis. BMC Pulm Med. 2024;24:620.
104. Erickson A, Brastianos P, Das S. 04. Assessment of efficacy and safety of osimertinib for patients with intracranial metastatic disease: a systematic review and meta-analysis. Neuro Oncol Adv. 2020;2:ii1.
105. Liu L, Bai H, Seery S, et al. Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: a systematic review and Bayesian network meta-analysis. Lung Cancer. 2021;158:74-84.
106. Ma J, Pang X, Zhang S, Huang L, Sun L, Han C. First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Sci Rep. 2024;14:22901.
107. Mei T, Wang T, Xu T, Zhou Q. Comparing the effectiveness and safety of first-line interventions in patients with advanced epidermal growth factor receptor-mutant non-small cell lung cancer, with particular focus on brain metastatic status: a systematic review and network meta-analysis. Clin Oncol. 2025;40:103776.
108. Wen L, Zhen J, Shan C, et al. Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis. Eur J Med Res. 2023;28:267.
109. Bian DJ, Lazaratos A, Maritan SM, et al. Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: a systematic review and meta-analysis. Heliyon. 2024;10:e29668.
110. Yi X, Song J, Gao R, et al. Efficacy of osimertinib in EGFR-mutated advanced non-small-cell lung cancer with different T790M status following resistance to prior EGFR-TKIs: a systematic review and meta-analysis. Front Oncol. 2022;12:863666.
111. Priantti JN, Vilbert M, Moraes FCA, et al. Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: a systematic review and meta-analysis. J Clin Oncol. 2024;42:8642.
112. Song C, Yang X. Osimertinib-centered therapy against uncommon epidermal growth factor receptor-mutated non-small-cell lung cancer- a mini review. Front Oncol. 2022;12:834585.
113. Zhou G, Guo L, Xu J, Tang K, Chen J. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024;16:17588359241227677.
114. Yao L, Zhang C, Li D, Xu L, Yang X. Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials. Medicine. 2024;103:e40320.
115. Qi Y, Xia X, Shao L, et al. An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Front Oncol. 2022;12:616546.
116. Grazini U, Markovets A, Ireland L, et al. Overcoming osimertinib resistance with akt inhibition in EGFRm-driven non-small cell lung cancer with PIK3CA/PTEN alterations. Clin Cancer Res. 2024;30:4143-54.
117. Peled N, Tufman A, Sequist L, et al. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. ESMO Open. 2025;10:105807.
118. Deng S, Sun C, Liu D, et al. Antibody-drug conjugates: a new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer. Pharmacol Res. 2026;223:108066.
119. Wang R, Chen Y, Li L, Zhang L, Zhang S. Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies. Cancer Drug Resist. 2025;8:61.
120. Maione P, Romano FJ, Gridelli C. Amivantamab plus lazertinib and platin-based chemotherapy plus osimertinib in EGFR-mutant NSCLC: how to choose among them and when is monotherapy with osimertinib still the best option? Curr Oncol. 2026;33:54.
121. Sankar K, Waissengrin B, Reckamp KL. The expanding landscape of next-generation EGFR tyrosine kinase inhibitors: have we reached capacity? J Thorac Oncol. 2025;20:1569-72.
122. Wang C, Wu W, Yan B, et al. The causal relationship between epigenetic aging and osteoporosis: a bi-directional Mendelian randomization study. J Transl Genet Genom. 2025;9:90-9.
123. Karri V, Dalia SM. Persistent IFN-γ signaling in acquired resistance to PD-(L)1 blockade in NSCLC. J Transl Genet Genom. 2025;9:352-8.
124. Prakashan D, PR R, Kaushik A, Gandhi S. Sustainable nanotechnology and artificial intelligence to empower image-guided therapy for precision healthcare. BME Front. 2025;6:0150.
125. Zhu H, Wang R, Qian J, et al. Leveraging large language models for predicting postoperative acute kidney injury in elderly patients. BME Front. 2025;6:0111.
